The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

LEBANON, N.H., April 15, 2026 /PRNewswire/ -- Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, congratulates GSK plc for recently ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning that ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing Submissions based on data from positive SWIFT and ANCHOR trials SWIFT-1 and -2 showed depemokimab reduced ...

GSK’s GSK two-phase III studies, which evaluated depemokimab for treating severe asthma characterized by type II inflammation, met their primary endpoints. The primary endpoints of the SWIFT-1 and ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

The ultra-long acting investigational biologic is administered once every 6 months as a subcutaneous injection. Depemokimab reduced the rate of exacerbations in patients with severe asthma with type 2 ...

Please provide your email address to receive an email when new articles are posted on . Depemokimab is a twice-yearly treatment. The FDA based depemokimab’s approval on phase 3 SWIFT-1 and SWIFT-2 ...